Agenus Inc. (NASDAQ:AGEN - Get Free Report) shares passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $3.30 and traded as high as $7.34. Agenus shares last traded at $7.06, with a volume of 6,804,832 shares changing hands.
Wall Street Analysts Forecast Growth
A number of research firms recently commented on AGEN. B. Riley reiterated a "buy" rating on shares of Agenus in a report on Monday, April 21st. HC Wainwright upgraded Agenus from a "neutral" rating to a "buy" rating and set a $25.00 price objective on the stock in a report on Wednesday, June 4th. Wall Street Zen upgraded Agenus from a "strong sell" rating to a "hold" rating in a report on Thursday, May 22nd. Finally, Robert W. Baird upped their price objective on Agenus from $4.00 to $6.00 and gave the company a "neutral" rating in a report on Wednesday, June 4th. Five investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $14.00.
Read Our Latest Report on Agenus
Agenus Stock Up 19.3%
The company has a market cap of $193.59 million, a PE ratio of -0.81 and a beta of 1.51. The business has a 50-day simple moving average of $4.45 and a 200-day simple moving average of $3.30.
Agenus (NASDAQ:AGEN - Get Free Report) last announced its earnings results on Monday, May 12th. The biotechnology company reported ($1.03) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.61) by $0.58. The firm had revenue of $24.07 million during the quarter, compared to analysts' expectations of $26.38 million. As a group, equities research analysts predict that Agenus Inc. will post -12.55 EPS for the current fiscal year.
Institutional Trading of Agenus
A number of institutional investors and hedge funds have recently added to or reduced their stakes in AGEN. B. Riley Financial Inc. purchased a new stake in shares of Agenus during the fourth quarter worth $2,074,000. Siren L.L.C. purchased a new stake in shares of Agenus during the first quarter worth $752,000. AQR Capital Management LLC increased its position in shares of Agenus by 3,080.3% during the first quarter. AQR Capital Management LLC now owns 441,486 shares of the biotechnology company's stock worth $664,000 after acquiring an additional 427,604 shares during the period. Gilead Sciences Inc. purchased a new stake in shares of Agenus during the fourth quarter worth $635,000. Finally, Northern Trust Corp increased its position in shares of Agenus by 14.8% during the fourth quarter. Northern Trust Corp now owns 208,933 shares of the biotechnology company's stock worth $572,000 after acquiring an additional 26,870 shares during the period. Hedge funds and other institutional investors own 61.46% of the company's stock.
About Agenus
(
Get Free Report)
Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.
Further Reading
Before you consider Agenus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agenus wasn't on the list.
While Agenus currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
